Stocks
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
AI Analyst Top Stocks
New
Top Insiders Stocks
Market Movers
TipRanks 50 Index
AI Stocks
Largest Companies by Market Cap
ETFs
Top ETFs by Upside
Top ETFs by Smart Score
Top Gainers/ Losers/ Active ETFs
Crypto
Bitcoin
Popular
Ethereum
Commodities
Gold
Options
Unusual Options Activity
Popular
Currency
EUR/USD
Ideas
Plans
Research Tools
Trending Stocks
Compare Stocks
Compare ETFs
Trump Dashboard
New
Daily Feeds
Daily Analyst Ratings
Daily Insider Trading Tracker
Calendars
Earnings Calendar
Dividend Calendar
Economic Calendar
IPO Calendar
Stock Splits
Stock Buybacks
FDA Calendar
Market Holidays
Calculators
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Economic Indicators
Inflation Rate
Unemployment Rate
Class Actions
Tools
Plans
Stock Screener
ETF Screener
Popular
Penny Stock Screener
Technical Analysis Screener
Screeners
Plans
Dividend Center
Best Dividend Stocks
Popular
Best High Yield Dividend Stocks
Dividend Aristocrats
Dividend Stock Comparison
New
Dividend Calculator
Dividend Returns Comparison
Dividend Calendar
Dividends
Plans
My Experts
Top Analysts
Top Financial Bloggers
Top-Performing Corporate Insiders
Top Hedge Fund Managers
Top Research Firms
Top Individual Investors
Experts
Plans
Portfolio
Plans
Trending News
More News >
News
Plans
Private Companies
Plans
Enterprise Solutions
Plans
Education
Personal Finance
How To Use TipRanks
TipRanks Labs
Glossary
FAQs
About Us
About TipRanks
Careers
Contact Us
Reviews
Mobile APP
Working with TipRanks
Enterprise Solutions
Advertise with Us
Top Online Brokers
Become an Affiliate
TipRanks News Wire
Follow Us
More
Plans
Plans
Plans
TOOLS
Portfolio
Watchlist
Top Insiders Stocks
Popular
Top Stocks
Popular
Market Movers
Compare stocks
Compare ETFs
Notification Center
News
Screeners
Stock Screener
ETF Screener
Popular
Penny Stock Screener
Technical Analysis Screener
Ideas
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
AI Analyst Top Stocks
New
Top Insiders Stocks
Research Tools
Compare Stocks
Compare ETFs
Trending Stocks
Daily Analyst Ratings
Daily Insiders Trades
Dividend Stocks
ETF Center
Top Gainers/losers/active ETFs
Trump Dashboard
New
Calculators
Dividend Calculator
Options Profit Calculator
Dollar Cost Averaging
Compound Interest Calculator
Mortgage Calculator
Auto Loan Calculator
Student Loan Calculator
401k Retirement Calculator
Calendars
Earnings Calendar
Dividend Calendar
Economic Calendar
IPO Calendar
Stock Splits
Stock Buybacks
FDA Calendar
Market Holidays
Dividends
Dividend Center
Best Dividend Stocks
Popular
Best High Yield Dividend Stocks
Dividend Aristocrats
Dividend Stock Comparison
New
Dividend Calculator
Dividend Returns Comparison
Dividend Calendar
Experts
Top Analysts
Top Financial Bloggers
Top-Performing Corporate Insiders
Top Hedge Fund Managers
Top Research Firms
Top Individual Investors
Market Movers
Top Gainers
Top Losers
Most Active
Premarket
After-hours
Private Companies
Personal Finance
Personal Finance Center
Mortgages
Loans
Investing & Retirement
Spending & Savings
Real Estate
Top Online Brokers
Enterprise Solutions
Plans & Pricing
More
Education
How To Use TipRanks
TipRanks Labs
Glossary
FAQs
About Us
About TipRanks
Contact Us
Careers
Reviews
Mobile APP
Working with TipRanks
Enterprise Solutions
Top Online Brokers
Become an Affiliate
TipRanks News Wire
Follow Us
STOCKS
SPY
QQQ
AAPL
NVDA
TSLA
AMZN
BABA
Log Out
Advertisement
Advertisement
FATE
Stock Latest News
Ratings
Gil Blum Maintains Hold Rating Amid Uncertainty on FT819 Durability and Rising Competition in Lupus Nephritis Cell Therapies
2d ago
FATE
Premium
Ratings
Tara Bancroft Reiterates Hold Rating as FT819’s Autoimmune Momentum Offsets Early-Stage, Regulatory and Execution Risks
2d ago
FATE
Premium
The Fly
Fate Therapeutics reports Q1 EPS (26c), consensus (28c)
2d ago
FATE
Premium
The Fly
Fate Therapeutics price target raised to $7 from $5 at H.C. Wainwright
12d ago
FATE
Premium
Pre-Earnings
FATE Upcoming Earnings Report: What to Expect?
12d ago
FATE
Premium
The Fly
Fate Therapeutics announces data presentation of FT839
30d ago
FATE
Premium
Ratings
Maintaining a Hold on Fate Therapeutics as FT819’s Clinical and Commercial Profile Remains Unclear
3M ago
FATE
Premium
The Fly
Fate Therapeutics reports Q4 EPS (77c), consensus (27c)
3M ago
FATE
Premium
The Fly
Fate Therapeutics presents updated Phase 1 data of FT819
5M ago
FATE
Premium
Company Announcements
Fate Therapeutics Reports Q3 Loss Amid Restructuring Efforts
6M ago
FATE
Premium
Company Announcements
Navigating Data Privacy Challenges: Fate Therapeutics’ Battle with Regulatory Compliance and Business Risks
6M ago
FATE
Premium
Ratings
Fate Therapeutics: Balancing Potential and Uncertainty with FT819’s Promise in Autoimmune Treatment
6M ago
FATE
Premium
The Fly
Fate Therapeutics reports Q3 EPS (27c), consensus (28c)
6M ago
FATE
Premium
The Fly
Fate Therapeutics upgraded to Buy from Neutral at H.C. Wainwright
7M ago
FATE
Premium
Pre-Earnings
Is FATE a Buy, Before Earnings?
7M ago
FATE
Premium
Company Announcements
Fate Therapeutics Advances CAR T-Cell Therapy with New Clinical Study
7M ago
FATE
Premium
Company Announcements
Fate Therapeutics’ Phase 1 Study: A Potential Game-Changer in Autoimmune Disease Treatment
7M ago
FATE
Premium
Company Announcements
Fate Therapeutics’ Innovative CAR T-Cell Therapy Study: A Potential Game-Changer in Cancer Treatment
7M ago
FATE
Premium
The Fly
Wedbush upgrades Fate Therapeutics to Outperform, raises target to $7
7M ago
FATE
Premium
Company Announcements
Fate Therapeutics Reports Promising Phase 1 Trial Results
7M ago
8K
FATE
Premium
The Fly
Fate Therapeutics upgraded to Outperform from Neutral at Wedbush
7M ago
FATE
Premium
Ratings
Hold Rating Maintained for Fate Therapeutics’ FT819 Amid Efficacy and Durability Concerns
7M ago
FATE
Show More
Trending
Indices
Stocks
ETFs
Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >
You need to enable JavaScript to run this app.
